- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Tyco to scoop up C.R. Bard
Another medical device manufacturer may soon join Tyco International. The multinational company, which has made a habit of gobbling up others, has signed a definitive agreement to buy C.R. Bard in a stock swap valued at about $3.2 billion, including the
Another medical device manufacturer may soon join Tyco International. The multinational company, which has made a habit of gobbling up others, has signed a definitive agreement to buy C.R. Bard in a stock swap valued at about $3.2 billion, including the assumption of net debt, based on Tyco’s May 29 closing share price of $57. Bard shareholders will receive Tyco shares valued (just prior to the Bard shareholder vote) at $60 for each share of Bard, subject to an adjustment should Tyco stock trade below $50 during a measurement period. Bard, which had 2000 revenues of $1.1 billion, is a leading medical devices manufacturer of products used for vascular, urological, and oncological diagnosis and intervention as well as surgical specialties. Tyco’s holdings include US Surgical and Mallinckrodt.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
